Longeveron (LGVN) Free Cash Flow Growth (1y) (2021 - 2026)
Longeveron (LGVN) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 38.94% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 96.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 152.82% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.34% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 58.53% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 31.57% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -53.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.17% |
| Mar 31, 2026 | 7.49% |
| Dec 31, 2025 | -56.41% |
| Sep 30, 2025 | -56.19% |
| Jun 30, 2025 | 21.08% |
| Mar 31, 2025 | -52.29% |
| Dec 31, 2024 | 18.63% |
| Sep 30, 2024 | 28.21% |
| Jun 30, 2024 | -1.47% |
| Mar 31, 2024 | 47.33% |
| Dec 31, 2023 | -75.27% |
| Sep 30, 2023 | 1.15% |
| Jun 30, 2023 | -39.96% |
| Mar 31, 2023 | -40.27% |
| Dec 31, 2022 | -49.03% |
| Sep 30, 2022 | -94.52% |
| Jun 30, 2022 | -13.58% |
| Mar 31, 2022 | -38.49% |
| Dec 31, 2021 | -223.78% |
| Sep 30, 2021 | -863.82% |